These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35899950)

  • 21. Characterizing and Exploring the Differences in Dissolution and Stability Between Crystalline Solid Dispersion and Amorphous Solid Dispersion.
    Wang X; Zhang L; Ma D; Tang X; Zhang Y; Yin T; Gou J; Wang Y; He H
    AAPS PharmSciTech; 2020 Sep; 21(7):262. PubMed ID: 32975680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral hesperidin-Amorphization and improved dissolution properties by controlled loading onto porous silica.
    Wei Q; Keck CM; Müller RH
    Int J Pharm; 2017 Feb; 518(1-2):253-263. PubMed ID: 27871833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic role of solid lipid and porous silica in improving the oral delivery of weakly basic poorly water soluble drugs.
    Yasmin R; Rao S; Bremmell K; Prestidge C
    Eur J Pharm Sci; 2017 Jan; 96():508-514. PubMed ID: 27793717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Porous Silica-Supported Solid Lipid Particles for Enhanced Solubilization of Poorly Soluble Drugs.
    Yasmin R; Rao S; Bremmell KE; Prestidge CA
    AAPS J; 2016 Jul; 18(4):876-85. PubMed ID: 27048207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antioxidant properties of probucol released from mesoporous silica.
    Lau M; Giri K; Garcia-Bennett AE
    Eur J Pharm Sci; 2019 Oct; 138():105038. PubMed ID: 31398394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mesoporous Silica Molecular Sieve based Nanocarriers: Transpiring Drug Dissolution Research.
    Pattnaik S; Pathak K
    Curr Pharm Des; 2017; 23(3):467-480. PubMed ID: 27784249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stable and Fast-Dissolving Amorphous Drug Composites Preparation via Impregnation of Neusilin
    Azad M; Moreno J; Davé R
    J Pharm Sci; 2018 Jan; 107(1):170-182. PubMed ID: 29031953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.
    McCarthy CA; Faisal W; O'Shea JP; Murphy C; Ahern RJ; Ryan KB; Griffin BT; Crean AM
    J Control Release; 2017 Mar; 250():86-95. PubMed ID: 28132935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization.
    Hörmann TR; Jäger N; Funke A; Mürb RK; Khinast JG; Paudel A
    Int J Pharm; 2018 Dec; 553(1-2):408-421. PubMed ID: 30326284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced dissolution and oral bioavailability of nifedipine by spontaneous emulsifying powders: effect of solid carriers and dietary state.
    Weerapol Y; Limmatvapirat S; Jansakul C; Takeuchi H; Sriamornsak P
    Eur J Pharm Biopharm; 2015 Apr; 91():25-34. PubMed ID: 25615879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method.
    Takeuchi H; Nagira S; Yamamoto H; Kawashima Y
    Int J Pharm; 2005 Apr; 293(1-2):155-64. PubMed ID: 15778053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of Drug-Silica Electrostatic Interactions on Drug Release from Mesoporous Silica-Based Oral Delivery Systems.
    Hate SS; Reutzel-Edens SM; Taylor LS
    Mol Pharm; 2020 Sep; 17(9):3435-3446. PubMed ID: 32790416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole.
    Kinnari P; Mäkilä E; Heikkilä T; Salonen J; Hirvonen J; Santos HA
    Int J Pharm; 2011 Jul; 414(1-2):148-56. PubMed ID: 21601623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancing oral bioavailability of poorly soluble drugs with mesoporous silica based systems: opportunities and challenges.
    Bremmell KE; Prestidge CA
    Drug Dev Ind Pharm; 2019 Mar; 45(3):349-358. PubMed ID: 30411991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced dissolution of valsartan-vanillin binary co-amorphous system loaded in mesoporous silica particles.
    Hashim Ali K; Mohsin Ansari M; Ali Shah F; Ud Din F; Abdul Basit M; Kim JK; Zeb A
    J Microencapsul; 2019 Jan; 36(1):10-20. PubMed ID: 30719944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superiority of amino-modified chiral mesoporous silica nanoparticles in delivering indometacin.
    Li J; Guo Y; Li H; Shang L; Li S
    Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):1085-1094. PubMed ID: 28776393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissolution enhancement of a model poorly water-soluble drug, atorvastatin, with ordered mesoporous silica: comparison of MSF with SBA-15 as drug carriers.
    Maleki A; Hamidi M
    Expert Opin Drug Deliv; 2016; 13(2):171-81. PubMed ID: 26636904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of mesoporous silica particles as drug carriers in hydrogels.
    Lunter DJ
    Pharm Dev Technol; 2018 Oct; 23(8):826-831. PubMed ID: 28826298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lyophilized silica lipid hybrid (SLH) carriers for poorly water-soluble drugs: physicochemical and in vitro pharmaceutical investigations.
    Yasmin R; Tan A; Bremmell KE; Prestidge CA
    J Pharm Sci; 2014 Sep; 103(9):2950-2959. PubMed ID: 24585389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of New Bexarotene-loaded Mesoporous Silica Systems for Topical Pharmaceutical Formulations.
    Vasile A; Ignat M; Zaltariov MF; Sacarescu L; Stoleriu I; Draganescu D; Dumitras M; Ochiuz L
    Acta Chim Slov; 2018 Mar; 65(1):97-107. PubMed ID: 29562115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.